Trastuzumab: Weighing the Benefits and the Risks

被引：2

作者：

Blaes, Anne H. ^{[1
]}

Dang, Chau ^{[2
]}

机构：

[1] Univ Minnesota, Div Hematol Oncol, Minneapolis, MN 55455 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2020年 / 112卷 / 12期

关键词：

HER2-POSITIVE BREAST-CANCER; ADJUVANT CHEMOTHERAPY; PLUS TRASTUZUMAB; COMBINATION; MULTICENTER; PACLITAXEL; PERTUZUMAB;

D O I：

10.1093/jnci/djaa055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1181 / 1182

页数：2

共 16 条

[1] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].

Cameron, David ;

Piccart-Gebhart, Martine J. ;

Gelber, Richard D. ;

Procter, Marion ;

Goldhirsch, Aron ;

de Azambuja, Evandro ;

Castro, Gilberto, Jr. ;

Untch, Michael ;

Smith, Ian ;

Gianni, Luca ;

Baselga, Jose ;

Al-Sakaff, Nedal ;

Lauer, Sabine ;

McFadden, Eleanor ;

Leyland-Jones, Brian ;

Bell, Richard ;

Dowsett, Mitch ;

Jackisch, Christian .

LANCET, 2017, 389 (10075) :1195-1205

[2] Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib [J].

Carey, Lisa A. ;

Berry, Donald A. ;

Cirrincione, Constance T. ;

Barry, William T. ;

Pitcher, Brandelyn N. ;

Harris, Lyndsay N. ;

Ollila, David W. ;

Krop, Ian E. ;

Henry, Norah Lynn ;

Weckstein, Douglas J. ;

Anders, Carey K. ;

Singh, Baljit ;

Hoadley, Katherine A. ;

Iglesia, Michael ;

Cheang, Maggie Chon U. ;

Perou, Charles M. ;

Winer, Eric P. ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) :542-+

[3] Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study [J].

Conte, P. ;

Frassoldati, A. ;

Bisagni, G. ;

Brandes, A. A. ;

Donadio, M. ;

Garrone, O. ;

Piacentini, F. ;

Cavanna, L. ;

Giotta, F. ;

Aieta, M. ;

Gebbia, V. ;

Molino, A. ;

Musolino, A. ;

Ferro, A. ;

Maltoni, R. ;

Danese, S. ;

Zamagni, C. ;

Rimanti, A. ;

Cagossi, K. ;

Russo, A. ;

Pronzato, P. ;

Giovanardi, F. ;

Moretti, G. ;

Lombardo, L. ;

Schirone, A. ;

Beano, A. ;

Amaducci, L. ;

Bajardi, E. A. ;

Vicini, R. ;

Balduzzi, S. ;

D'Amico, R. ;

Guarneri, V. ;

Giarratano, Tommaso ;

McMahon, Laura ;

De Salvo, Gian Luca ;

Dieci, Maria Vittoria ;

Maiorana, Antonio ;

Ficarra, Guido ;

Caggia, Federica ;

Grisolia, Deborah ;

Bartolini, Stefania ;

Lorusso, Vito ;

Ardito, Raffaele ;

Tartarone, Alfredo ;

Vanella, Paola ;

Taverniti, Cristiana ;

Porpiglia, Mauro ;

Spanu, Pier Giorgio ;

Biglia, Nicoletta ;

Andreis, Daniele .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2328-2333

[4] PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. [J].

Earl, Helena Margaret ;

Hiller, Louise ;

Vallier, Anne-Laure ;

Loi, Shrushma ;

Howe, Donna ;

Higgins, Helen B. ;

McAdam, Karen ;

Hughes-Davies, Luke ;

Harnett, Adrian Nigel ;

Ah-See, Mei-Lin ;

Simcock, Richard ;

Rea, Daniel William ;

Mansi, Janine ;

Abraham, Jean ;

Caldas, Carlos ;

Hulme, Claire ;

Miles, David ;

Wardley, Andrew M. ;

Cameron, David A. ;

Dunn, Janet .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[5] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia Valeria ;

Magazzu, Domenico ;

McNally, Virginia ;

Douthwaite, Hannah ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2016, 17 (06) :791-800

[6] NCCN Guidelines® Insights Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines [J].

Gradishar, William J. ;

Anderson, Benjamin O. ;

Balassanian, Ron ;

Blair, Sarah L. ;

Burstein, Harold J. ;

Cyr, Amy ;

Elias, Anthony D. ;

Farrar, William B. ;

Forero, Andres ;

Giordano, Sharon Hermes ;

Goetz, Matthew P. ;

Goldstein, Lori J. ;

Isakoff, Steven J. ;

Lyons, Janice ;

Marcom, P. Kelly ;

Mayer, Ingrid A. ;

McCormick, Beryl ;

Moran, Meena S. ;

O'Regan, Ruth M. ;

Patel, Sameer A. ;

Pierce, Lori J. ;

Reed, Elizabeth C. ;

Salerno, Kilian E. ;

Schwartzberg, Lee S. ;

Sitapati, Amy ;

Smith, Karen Lisa ;

Smith, Mary Lou ;

Soliman, Hatem ;

Somlo, George ;

Telli, Melinda ;

Ward, John H. ;

Shead, Dorothy A. ;

Kumar, Rashmi .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (04) :433-+

[7] Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial [J].

Joensuu, Heikki ;

Fraser, Judith ;

Wildiers, Hans ;

Huovinen, Riikka ;

Auvinen, Paivi ;

Utriainen, Meri ;

Nyandoto, Paul ;

Villman, Kenneth K. ;

Halonen, Paivi ;

Granstam-Bjorneklett, Helena ;

Lundgren, Lotta ;

Sailas, Liisa ;

Turpeenniemi-Hujanen, Taina ;

Tanner, Minna ;

Yachnin, Jeffrey ;

Ritchie, Diana ;

Johansson, Oskar ;

Huttunen, Teppo ;

Neven, Patrick ;

Canney, Peter ;

Harvey, Vernon J. ;

Kellokumpu-Lehtinen, Pirkko-Liisa ;

Lindman, Henrik .

JAMA ONCOLOGY, 2018, 4 (09) :1199-1206

[8] Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) [J].

Mavroudis, D. ;

Saloustros, E. ;

Malamos, N. ;

Kakolyris, S. ;

Boukovinas, I. ;

Papakotoulas, P. ;

Kentepozidis, N. ;

Ziras, N. ;

Georgoulias, V. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1333-1340

[9] Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 [J].

Perez, Edith A. ;

Romond, Edward H. ;

Suman, Vera J. ;

Jeong, Jong-Hyeon ;

Sledge, George ;

Geyer, Charles E., Jr. ;

Martino, Silvana ;

Rastogi, Priya ;

Gralow, Julie ;

Swain, Sandra M. ;

Winer, Eric P. ;

Colon-Otero, Gerardo ;

Davidson, Nancy E. ;

Mamounas, Eleftherios ;

Zujewski, Jo Anne ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3744-+

[10] 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial [J].

Pivot, Xavier ;

Romieu, Gilles ;

Debled, Marc ;

Pierga, Yves ;

Kerbrat, Pierre ;

Bachelot, Thomas ;

Lortholary, Alain ;

Espie, Marc ;

Fumoleau, Pierre ;

Serin, Daniel ;

Jacquin, Jean-Philippe ;

Jouannaud, Christelle ;

Rios, Maria ;

Abadie-Lacourtoisie, Sophie ;

Venat-Bouvet, Laurence ;

Cany, Laurent ;

Catala, Stephanie ;

Khayat, David ;

Gambotti, Laetitia ;

Pauporte, Iris ;

Faure-Mercier, Celine ;

Paget-Bailly, Sophie ;

Henriques, Julie ;

Grouin, Jean Marie .

LANCET, 2019, 393 (10191) :2591-2598

← 1 2 →